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Abstract
In England and Wales, the National Institute for Health and Clinical Excellence (NICE) has provided guid-
ance [technology appraisals (TAs) 130, 186, 195, 198 and 225] on the use of biologic drugs for the treat-
ment of RA. This is based on an analysis of efficacy, safety and cost-effectiveness, and has resulted in a
complex management pathway that restricts freedom to prescribe biologics according to their licensed
indications. Specifically, TNF antagonists are the only class of biologics that can be used first line in
DMARD-inadequate responders, and only in patients with a persistent 28-joint DAS score of 55.1.
Alternative biologic agents are denied to those with contraindications to anti-TNF drugs and are also
not supported following intolerance to TNF antagonists. Rituximab is the only class of biologic permitted
after TNF antagonist inefficacy, in the absence of a contraindication to its use, whereas abatacept and
tocilizumab are licensed and may be a more efficacious choice at this stage in some patient groups.
Furthermore, for patients who demonstrate sequential inadequate responses, treatment is restricted to one
TNF antagonist, rituximab and tocilizumab, whereas abatacept is only a permitted choice when rituximab is
contraindicated or has been withdrawn because of an adverse event. In this review, we discuss the
treatment algorithm published by NICE, and suggest alternatives where perceived deficiencies exist.
Key words: rheumatoid arthritis, biologic agents, guidelines, TNF antagonists, adalimumab, etanercept,
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Patients with RA and their physicians have been extremely
fortunate over the last decade in having four classes of
biologic agents licensed to combat the disease. This has
led to a seismic shift in RA management resulting in dis-
ease remission, or at least low disease activity, as the
therapeutic goal [1, 2]. However, in England and Wales
the ability to deliver evidenced-based practice has been
restricted by the National Institute for Health and Clinical
Excellence (NICE) following the publication of five
technology appraisals (TAs 130, 186, 195, 198 and 225)
providing guidance on the use of biologic drugs based on
an analysis of efficacy, safety and cost-effectiveness
[36]. The result is a complex management pathway that
the majority of health commissioners in England and
Wales insist rheumatologists follow (Fig. 1).
Internationally, while not binding, these guidelines may
also carry substantial influence. In this review we will at-
tempt to navigate this algorithm and suggest alternatives
where perceived deficiencies exist. Table 1 lists biologic
agents according to licensed and NICE-approved status
in different clinical scenarios.
Initial biologic therapy
The decision to initiate a biologic drug has been ad-
dressed by leading rheumatology societies worldwide
(e.g. BSR, EULAR, ACR). A common consensus is that a
biologic should be started in patients who fail to achieve a
28-joint DAS (DAS-28)<3.2 after treatment with trad-
itional DMARDs [711]. This contrasts with NICE TA 130
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Biologic agents for RA(October 2007) that recommends anti-TNF therapies be
started in patients who have a persistently elevated
DAS-28>5.1, after failure of two DMARDs (including
MTX, unless contraindicated) taken over a minimum time
of 6 months each. This remains the current standard
of practice in England and Wales, being at variance with
many published guidelines and standards in the European
Union and the USA, which emphasize the importance
of not delaying the start of biologic therapy when required
[1, 2]. The implication for patients with a DAS-28 between
3.2 and 5.1 is that improvement in disease activity may
only be achieved by continuing traditional DMARDs and
CSs. However, data from the Early Rheumatoid Arthritis
Network, a prospective inception cohort of early RA in
England and Wales, has shown that only 27% of patients
with DAS-28 3.25.1 achieve a DAS-28<3.2 at Year
2 and 35% at Year 3 in routine care using conventional
DMARDs [12]. Furthermore, this data set has also shown
that patients with a DAS persistently in this range fair
poorly, with sustained and substantial disability as docu-
mented by poor scores of function. For those living in
England and Wales the time has surely come to pay
greater attention to this patient group with a persistent
DAS-28 of 3.25.1 despite conventional therapies, and
permit the use of biologics in order to achieve remission,
or at least low disease activity, according to current prin-
ciples of best practice [1, 2, 11].
MTX intolerance
It is clear that outcomes are improved if TNF antagonists
are co-prescribed with MTX [13, 14]. As such, NICE con-
curs with other guidelines that MTX remains the
cornerstone DMARD for RA. However, in routine care
>30% of patients receive biologics as monotherapy
[15, 16]. In those patients who are MTX intolerant, NICE
allows the use of adalimumab, etanercept (TA 130) and
certolizumab (TA 186) as monotherapy, in keeping with
drug licences. In practice, clinicians may choose to
co-prescribe an alternative DMARD to MTX, on the as-
sumption that the benefit is not drug specific, but rather
an effect of overall immunomodulation. An alternative
first-line biologic may be tocilizumab, as this is licensed
without MTX in DMARD-inadequate responder (IR) pa-
tients. There is randomized controlled trial (RCT) evidence
for the use of tocilizumab as monotherapy [17] and in
combination with non-MTX DMARDs [18]. Tocilizumab is
therefore a legitimate choice as a first-line biologic in pa-
tients where MTX is not tolerated, but is not currently rec-
ommended under NICE guidelines.
Contraindications to TNF antagonists
Where contraindications to TNF antagonists exist, NICE
provides no alternative first-line biologic option. The sum-
mary of product characteristics (SmPC) for anti-TNF drugs
list active tuberculosis or other severe infection including
sepsis or risk of sepsis, active infection including chronic
or localized infection, and opportunistic infection, as well
as moderate to severe heart failure [New York Heart
Association (NYHA) Class III/IV] as contraindications to
their use. Clinicians must also balance the risk/benefit of
a range of other conditions listed as precautions to the
use of TNF antagonists, such as history of malignancy,
blood dyscrasias, demyelinating disease, chronic ob-
structive pulmonary disease, vasculitis, as well as viral
TABLE 1 Biologic agents for RA listed according to licensed and NICE-approved status in different clinical scenarios
Scenario
MTX tolerant MTX intolerant
NICE approved Licensed options NICE approved Licensed options
DMARD-IR Adalimumab, certolizumab
pegol, etanercept, goli-
mumab, infliximab
Adalimumab, certolizu-
mab pegol, etanercept,
golimumab, infliximab,
abatacept, tocilizumab
Adalimumab,
certolizumab
pegol, etanercept
Adalimumab,
certolizumab
pegol, etanercept,
tocilizumab
DMARD-IR,
anti-TNF contraindication
Abatacept, tocilizumab Tocilizumab
Anti-TNF intolerant Alternative from adalimu-
mab, certolizumab
pegol, etanercept, goli-
mumab, infliximab
Adalimumab, certolizu-
mab pegol, etanercept,
golimumab, infliximab,
abatacept, rituximab,
tocilizumab
Alternative from
adalimumab,
certolizumab
pegol, etanercept
As DMARD-IR
Anti-TNF ineffective Rituximab As anti-TNF intolerant Alternative from
adalimumab,
etanercept
As DMARD-IR
Anti-TNF ineffective,
rituximab contraindication
Adalimumab, etanercept,
infliximab, abatacept,
tocilizumab
As DMARD-IR Alternative from
adalimumab,
etanercept
As DMARD-IR
Rituximab intolerant As anti-TNF ineffective,
rituximab
contraindication
As DMARD-IR Not applicable Not applicable
Rituximab ineffective Tocilizumab As DMARD-IR Not applicable Not applicable
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Patrick D. W. Kiely et al.and alcoholic hepatitis. These disorders are sufficiently
common that a significant proportion of patients will
either be excluded from receiving TNF antagonists, or
treated with trepidation. In this situation, an alternative
biologic should be available, as risk/benefit analysis may
confer a preference over anti-TNF drugs. Both abatacept
and tocilizumab are licensed for first-line biologic use
(rituximab is not) on the basis of trial evidence in
DMARD-IR patients [1921]. They may therefore be legit-
imately considered as alternative first-line biologics, espe-
cially where relative and absolute contraindications to TNF
antagonists exist. At present this is not recommended
under NICE guidelines.
Intolerance to first TNF antagonist
within 6 months
In this situation, NICE (TAs 130 and 186) allows a switch
within anti-TNF class. However, NICE provides no guid-
ance for patients who have responded but develop an
adverse event after the first 6 months of therapy.
These patients should also be allowed to switch to an
alternative TNF antagonist. Furthermore, there is no guid-
ance if the patient is also intolerant to the second or third
anti-TNF agent. Arguably these patients are effectively at
the first biologic stage, because intolerance has denied
them the opportunity of a therapeutic response to TNF
antagonists. Evidence exists that such patients may re-
spond to a different class of biologic, including abatacept,
rituximab and tocilizumab. Abatacept and tocilizumab are
licensed in DMARD and anti-TNF-IR patients, and rituxi-
mab is licensed for patients who have been intolerant to
one or more TNF antagonists. Therefore, they may all be
used legitimately at this juncture. Of these, tocilizumab
can be given as monotherapy in MTX-intolerant patients.
Nevertheless, none of these options are currently recom-
mended by NICE guidelines.
Poor efficacy of first anti-TNF drug in
MTX-intolerant patients
In this situation, NICE (TA 195) supports a within-class
switch to either adalimumab or etanercept monotherapy.
Certolizumab is not covered by TA 195, but would be
an acceptable alternative. Thus there is then no guidance
if these too are ineffective. Although NICE allows a switch
to another biologic class in this situation in MTX-tolerant
patients (TAs 195 and 198), there is no allowance for
MTX-intolerant patients. A legitimate alternative would
be tocilizumab, which is licensed for monotherapeutic
use in MTX-intolerant patients and has proven efficacy
in anti-TNF-IR patients; however, in the key TNF-IR trial,
all patients were co-prescribed MTX [22].
Poor efficacy of first anti-TNF drug
in MTX-tolerant patients
NICE (TA 195) supports rituximab alone as the second-line
biologic option, assuming no contraindications exist to its
use. This is a logical and appropriate course, especially for
patients who are seropositive for RF and/or
anti-citrullinated protein antibodies ACPAs. However,
rituximab is not unique among the biologics in working
well in this cohort. In contrast, EULAR guidelines recom-
mend a choice at this stage between all classes of
licensed biologics [10], which allows clinicians freedom
to use biomarker and other characteristics to individualize
therapy. Rituximab has proven efficacy in anti-TNF-IR pa-
tients [23]; however, some uncertainty exists over future
treatment options if hypogammaglobulinaemia develops
following repeat cycles. As such, guidance to use rituxi-
mab as the only second-line biologic is constrictive, out-
side the approach adopted by EULAR, and likely to lead
to certain patients not being treated with the most appro-
priate class of biologic at this stage. This is especially true
of those patients who are both RF and ACPA negative,
where the evidence (mainly from MTX-IR RCTs) suggests
that this group does not benefit as much as those patients
who possess these antibodies [2325].
Poor efficacy of first anti-TNF drug in
MTX-tolerant patients where rituximab
is contraindicated
NICE allows a switch within the anti-TNF class or the use
of abatacept (TA 195) or tocilizumab (TA 198). NICE TA
195 refers to the rituximab SmPC for definitions that
would contraindicate its use, these being active, severe
infection, the severely immunocompromised and those
with severe heart failure (NYHA Class IV) or severe uncon-
trolled cardiac disease. As previously mentioned, in clin-
ical practice there is hesitancy to prescribe rituximab
to antibody-negative patients, given the lower likelihood
of clinical benefit [2325]. Thus seronegativity for RF
should allow access to another biologic class with a
potentially higher likelihood of response. NICE provides
no guidance regarding therapeutic options if the first-
choice second-line biologic agent is ineffective or not tol-
erated. There is no reason to assume, however, that a
further switch between classes would not yield benefit in
the rituximab-contraindicated population.
Intolerance to rituximab
NICE allows switching to an alternative anti-TNF (TA 195)
or abatacept (TA 195) or tocilizumab (TA 198) if rituximab
is not tolerated, but gives no further guidance if this next
option is not tolerated or ineffective. There is no evidence
to suggest that a further between-class switch (fourth-line
biologic) would be ineffective or not tolerated. The treat-
ment alternatives at this stage are limited and patients in
this situation should have an opportunity to receive a trial
of all licensed biologics, particularly as our current ability
to match a biologic with an individual cannot exclude the
chance of response.
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Despite the absolute absence of evidence, NICE supports
a switch to tocilizumab alone if rituximab is inefficacious
(TA 198). This contrasts with the rituximab-intolerant
population, where a second anti-TNF agent or abatacept
are also allowed. This is inconsistent guidance, and the
choice of either a switch back to a second TNF antagonist
or abatacept or tocilizumab should be permitted for
rituximab-IR patients.
At present, if a patient is MTX tolerant but fails to re-
spond to each biologic in turn (with no contraindications
or intolerance), the NICE algorithm (Fig. 1) sequences
anti-TNF followed by rituximab and then tocilizumab, with
no option to use abatacept, or to switch within anti-TNF
class. This guidance, if adhered to, is contrary to the evi-
dence base [26, 27], and will deny patients all options to
achieve a state of low disease activity or remission.
For patients who develop intolerance to biologics, the
NICE algorithm (Fig. 1) is also inconsistent. At the anti-TNF
stage the patient cannot move to another class of bio-
logic, despite both abatacept and tocilizumab being
licensed for DMARD-IR patients with good evidence for
efficacy [1921]. At the rituximab stage a patient can pro-
gress to abatacept or tocilizumab if intolerant, yet may
only be treated with tocilizumab if rituximab is ineffective.
These are anomalies that are not supported by data and
prevent the use of the right drug at the right time.
Individualizing biologic therapy
Treatment algorithms as well as cost-effectiveness will be
transformed by the ability to match an individual patient to
a biologic, based on the mode of action and likely toler-
ability. The risk of infection is particularly important, as all
classes are associated with increased risk, with differ-
ences in half-life governing the speed of elimination. The
rates of serious infections quoted in the SmPC for each
biologic agent are shown in Table 2. The following high-
lights the benefits and drawbacks of abatacept, rituximab
and tocilizumab as therapeutic options in relation to TNF
antagonists.
Abatacept
There is extensive RCT evidence for efficacy of abatacept
in MTX-IR and TNF-IR RA patients, including those sero-
positive and seronegative for RF, and it is licensed in com-
bination with MTX in both MTX-IR and TNF-IR patients
[20, 21, 26, 28]. Infusion reactions are rare, and the
onset of action is slower than TNF antagonists, but incre-
mental benefit is reported beyond 1 year of treatment. As
with all biologics, abatacept is contraindicated in severe
and uncontrolled infection. The rate of serious infections
quoted in the SmPC is modest (Table 2) and consistent
with expectations based on RA cohorts treated with con-
ventional DMARDs. This may relate to mode of action, as
abatacept modulates T-cell co-stimulation without deplet-
ing or completely inhibiting T cells. Thus, for patients with
an increased risk of sepsis, the benefit/risk profile of aba-
tacept appears to be favourable, with the possible excep-
tion of those aged >65 years, where the incidence of
serious infection is reported to be higher than those <65
years (SmPC). Reassuringly in RCTs, no increased
autoantibody- cardiovascular- or malignancy-related ad-
verse events over that expected in an RA population are
reported, and abatacept is not contraindicated in patients
with heart failure.
Rituximab
There is extensive RCT evidence for efficacy of rituximab
in MTX-IR and TNF-IR RA patients [23, 29], although it
is only licensed in TNF-IR patients in combination with
MTX. Rituximab appears particularly suited to patients
TABLE 2 Biologic agent comparisons, incidence of serious infections
Biologic
drug
Speed of
onset Half-life Incidence of serious infections
Contraindicated
in heart failure
Adalimumab Fast 14 (1020) days 4.3 per 100 patient-years vs 3.0 per 100
patient-years in placebo and active
control-treated patients
Yes
a
Certolizumab pegol Fast 14 days 6.0 per 100 patient-years vs 2.0 per 100
patient-years placebo
Yes
a
Etanercept Fast 4 days (70132 hours) 6.3% of RA patients treated for up to 48
months
No
b
Golimumab Fast 915 days 5 per 100 patient-years vs 6 per 100
patient-years for control patients (1 year
data)
Yes
a
Infliximab Fast 89.5 days Data not quoted in SmPC Yes
a
Rituximab Slow 20.8 (8.5-35.9) days Approximately 4 per 100 patient-years Yes
c
Abatacept Slow 13 (8-25) days 2.87 per 100 patient-years; 1.8% vs 1.0% of
placebo-treated
No
Tocilizumab
(8mg/kg)
Fast 13 days 5.3 per 100 patient-years vs 3.9 per 100
patient-years in placebo+DMARD group
No
Source: SmPC.
aNYHA Grade III and IV;
bnot contraindicated but SmPC advises caution;
cNYHA Grade IV.
28 www.rheumatology.oxfordjournals.org
Patrick D. W. Kiely et al.with B-cell-driven disease, including autoantibody positiv-
ity (RF, ACPA, ANA), hypergammaglobulinaemia, nodules
and features of secondary SS. Rituximab is contraindi-
cated in patients with NYHA Class IV heart failure or
severe uncontrolled cardiac disease, and evidence sug-
gests that it is less suited to seronegative patients [2325].
The duration of each rituximab infusion and high fre-
quency of infusion-related reactions, including a cytokine
release syndrome accompanied by hypotension and
bronchospasm in 10% of the patients, places particular
responsibility on clinicians. The rate of serious infection
quoted in the SmPC is similar to TNF antagonists
(Table 2). Hypogammaglobulinaemia is an unknown con-
cern with respect to the safety of rituximab in the long
term or after switching to another biologic agent or trad-
itional DMARD. Similarly, long-term B-cell depletion, in
some patients lasting for years, is of unknown conse-
quence for the patient and the safety of future therapies.
The inability to predict or reverse B-cell depletion provides
some hesitancy to commit a patient to rituximab, espe-
cially when the other biologic classes may be used with
similar efficacy and greater flexibility in the face of toxicity,
including shorter half-life.
Tocilizumab
There is extensive RCT evidence for the efficacy of tocili-
zumab in MTX-IR and TNF-IR RA patients, including those
seropositive and seronegative for RF and as a monother-
apeutic agent [1719, 22]. Tocilizumab is licensed in both
MTX-IR and TNF-IR patients, may be used without MTX,
and the onset of action is similar to TNF antagonists.
Tocilizumab appears particularly suited to patients with
features of IL-6-driven disease, including high CRP,
anaemia of chronic disease, systemic involvement and
fatigue. The rate of serious infection quoted in the
SmPC and recent meta-analysis is similar to TNF antag-
onists (Table 2) [30]. However, inhibition of CRP and neu-
tropenia in some patients (3.4%) requires vigilance, as
signs and symptoms of sepsis may be diminished.
Gastrointestinal perforation in the presence of diverticular
disease has been reported, and tocilizumab should be
used with particular caution in these patients. Thus the
benefit/risk profile of tocilizumab with respect to infection
does not appear to be any more favourable than TNF an-
tagonists. Reassuringly, in RCTs no increased autoanti-
body, cardiovascular- or malignancy-related adverse
events have been reported, and tocilizumab is not contra-
indicated in patients with heart failure. Regular monitoring
of lipids, hepatic enzymes, neutrophils and platelets is
required, and this may influence the benefit/risk analysis
in some patients.
In conclusion, the optimal sequencing of biologic
agents is currently unknown. Until patient profiling with
robust biomarkers becomes available, treatment deci-
sions remain guided by the licensed indications and the
extensive evidence base of efficacy in varied situations.
This must be balanced with the likely risk of toxicity with
each class of biologic. The current NICE TAs restrict this
process, not least in preventing the use of biologics in
patients with a DAS-28 above a minimal acceptable
target of 3.2 but <5.1, and in constraining choices par-
ticularly for MTX-intolerant patients (anti-TNF agents only)
or serial IR patients (no switching within anti-TNF class or
use of abatacept). This review provides an analysis of the
situations where alternatives arise and has suggested a
legitimate course of action in each case. Our goal as
rheumatologists remains one of achieving remission in
all RA patients in order to maximize physical, psycho-
logical, and economic outcomes.
Rheumatology key messages
. Biologic agents are denied to those with contrain-
dications to anti-TNF drugs.
. Alternative biologics are not supported following
intolerance to anti-TNF agents.
. Sequential IR restricts treatment to one anti-TNF
agent, rituximab and tocilizumab.
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